5006802025-10-012025-12-315006802025-04-012025-12-315006802025-10-012025-12-31in-capmkt:OtherExpenses1Member5006802025-04-012025-12-31in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares500680PFIZERNOTLISTEDINE182A01018Pfizer LimitedMain BoardEquity2025-04-012026-03-312026-02-092026-01-30INRCroresQuarterlyThird quarterSingle segmentPharmaceuticals2026-02-0915:00:002026-02-0916:45:00Not applicablefalsefalseNot Applicable2025-10-012025-12-31UnauditedStandalone64503000003821000006832400000677800000145150000011840000010030000001990000014260000091770000043309000002501500000-5820000001919500000580000000-7890000050110000001418400000000014184000001870000014371000004575000001031.0131.010031.0131.011.The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on February 09, 2026. <BR> <BR> 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). <BR> <BR> 3.The financial results for the quarter and nine months ended December 31, 2025 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in <BR> <BR> 4. Exceptional items of Rs. 58.20 crore for the quarter and nine months ended December 31, 2025 include <BR> <BR> During the quarter, the Company has entered into an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium. The charge of Rs.39.58 crore includes personnel separation cost of field force and marketing teams as a result of the said arrangement and also includes personnel separation cost for other support functions. <BR> <BR> Effective 21 November 2025, the Government of India has consolidated several existing labour laws into a unified framework consisting of four Labour Codes, collectively known as the New Labour Codes. The Company has carried out an assessment based on the best available information and legal opinion, which has resulted in increase in the provision for employee benefits by Rs. 18.62 crore. The incremental impact is primarily due to change in wage definition. Considering the materiality and non-recurring nature of this impact, the Company has accounted such incremental impact under Exceptional items in the financial results for the quarter and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <BR> <BR> 5.Exceptional Items for the Year ended March 31, 2025 relates to Net gain of Rs.172.81 crore net of carrying value of Rs. 31.75 crore and cost to sell - Premium and other charges Rs. 59.84 crore, net of recovery on account of assignment of Lease of MIDC Land and Sale of Building constructed on such land. <BR> <BR> 6.The Company has only one segment which is Pharmaceuticals. Therefore, disclosure relating to segments is not applicable and accordingly not made. <BR> <BR> 7.The Company does not have any subsidiary company or associate company or joint venture company as at December 31, 2025.2025-04-012025-12-31UnauditedStandalone1890420000014723000002037650000022647000004907000000-5322000002907900000737000004295000002675400000127260000007650500000-58200000070685000001908800000-6640000018424000000522610000000005226100000400000522650000045750000010114.24114.2400114.24114.24Other Expenses917700000Other Expenses2675400000-25100000-600000640000020000018700000400000